Chemotherapy for hormone-refractory prostate cancer: beauty is in the eye of the beholder (Q34057806)

30 July 2017

1 reference

title

Chemotherapy for hormone-refractory prostate cancer: beauty is in the eye of the beholder (English)

1 reference

30 July 2017

1 reference

1 reference

Beer T

1

1 reference

30 July 2017

Raghavan D

series ordinal

2

1 reference

30 July 2017

publication date

1 October 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

45

1 reference

30 July 2017

issue

2

1 reference

30 July 2017

page(s)

184-193

1 reference

Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Science, language, intuition, and the many meanings of quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

A critical analysis of response criteria in patients with prostatic cancer treated with CIS-diamminedichloride platinum II

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Increased therapeutic index of antineoplastic drugs in combination with intracellular histamine antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

An EORTC phase II study of vindesine in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Oral estramustine and oral etoposide for hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Treatment response criteria for prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Weekly doxorubicin in endocrine-refractory carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Flow microfluorometry and transrectal fine-needle biopsy in the classification of human prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

DNA pattern and cytological findings in fine‐needle aspirates of untreated prostatic tumors. A flow‐cytofluorometric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

An immunocytochemical analysis of TGFα expression in benign and malignant prostatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Expression of the multidrug resistance gene in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Oral cyclophosphamide for the management of hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Phase II trial of ifosfamide in the treatment of metastatic hormone-refractory patients with prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Comparison of Estramustine Phosphate, Methotrexate and cis-Platinum: in Patients with Advanced1 Hormone Refractory Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Results of a clinical trial in humans with refractory cancer of the intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine-HCl, in combination with various single antineoplastic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine in combination with cyclophosphamide: an active, low-toxicity regimen for metastatic hormonally unresponsive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

A phase ii trial of oral estramustine and oral etoposide in hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0045%2820001001%2945%3A2%3C184%3A%3AAID-PROS13%3E3.0.CO%3B2-K

10.1002/1097-0045(20001001)45:2<184::AID-PROS13>3.0.CO;2-K

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference